<div id="readability-page-1"><div id="block-content"> Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine how upcoming GLP-1 patent expirations could reshape the drug delivery device market, and experts discuss the key forces driving renewed growth in radiopharmaceuticals.FDA has priority review of the supplemental biologics license application for a once-weekly subcutaneous formulation of Leqembi, pushing the agency’s action date back by three months. The application seeks approval for a more convenient administration option for patients with early Alzheimer disease and comes as demand grows for therapies that can reduce the burden associated with infusion-based treatment. The agency requested additional information related to the submission, though no new clinical studies were required.As GLP-1 therapies continue reshaping the metabolic disease market, attention is increasingly turning toward the of key patents and what that could mean for both generics and drug delivery technologies. Industry observers note that the transition could dramatically alter procurement strategies and intensify competition around injection devices, autoinjectors, and delivery platforms tied to obesity and diabetes treatments. With multiple companies expected to pursue follow-on or generic versions of blockbuster GLP-1 drugs in the coming years, device differentiation may become a critical competitive factor.Finally, radiopharmaceuticals are experiencing as advances in targeting technology, isotope production, and clinical validation continue to expand the field’s potential in oncology. Industry experts point to growing investment activity and an increasing number of strategic partnerships as major pharmaceutical companies seek exposure to a modality capable of delivering highly targeted cancer treatment.Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com. </div></div>

The FDA has extended its priority review of a subcutaneous formulation of Leqembi for early Alzheimer’s patients, delaying the action date by three months. Analysts are also focusing on upcoming GLP-1 patent expirations, which may impact the drug delivery device market, intensifying competition for injection devices. Additionally, advancements in radiopharmaceuticals are driving growth in oncology, with increased investment and strategic partnerships among major pharmaceutical companies.

Pharmexec

Eli Lilly

Novo Nordisk AS

SPDR S&P Health Equip

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long NVO ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Defiance Daily Target 2X Long LLY ETF

iShares Biotechnology ETF

iShares US Pharma

VG Health

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares US Medical Devices

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

<![CDATA[Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA]]>